Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

Subjects

Subjects :

ONCOL 3: Translational research.

Details

Database :

OAIster

Notes :

Veeger, N.J. author., Kooy, M.v. author., Beeker, A. author., Weerdt, O. de author., Groot, M. de author., Alhan, C. author., Hoogendoorn, M. author., Laterveer, L. author., Loosdrecht, A.A. van de author., Koedam, J. author., Vellenga, E. author., Huls, G.A. author.

Accession number :

edsoai.on1443238424